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Available online 26 October 2016The Golgi apparatus (GA) is a highly dynamic organelle, which is mainly involved in the post-translational pro-
cessing and targeting of cellular proteins and which undergoes signiﬁcant morphological changes in response to
different physiological and pathological conditions. In the present study, we have analyzed the possible alter-
ations of GA in neurons from the temporal neocortex and hippocampus of Alzheimer's disease (AD) patients,
using double immunoﬂuorescence techniques, confocal microscopy and 3D quantiﬁcation techniques. We
found that in AD patients, the percentage of temporal neocortical and CA1 hippocampal pyramidal neurons
with a highly altered GA is much higher (approximately 65%) in neurons with neuroﬁbrillary tangles (NFT)
than in NFT-free neurons (approximately 6%). Quantitative analysis of the surface area and volume of GA ele-
ments in neurons revealed that, compared with NFT-free neurons, NFT-bearing neurons had a reduction of ap-
proximately one half in neocortical neurons and one third in CA1 neurons. In both regions, neurons with a
pre-tangle stage of phospho-tau accumulation had surface area and GA volume values that were intermediate,
that is, between those of NFT-free and NFT-bearing neurons. These ﬁndings support the idea that the progressive
accumulation of phospho-tau is associated with structural alterations of the GA including fragmentation and a
decrease in the surface area and volume of GA elements. These alterations likely impact the processing and traf-
ﬁcking of proteins, which might contribute to neuronal dysfunction in AD.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The Golgi apparatus (GA) is an essential organelle in the processing
and targeting of cellular proteins, and its disruption is related to neuro-
nal dysfunctions and human diseases (Gonatas et al., 2006; Hu et al.,
2007). It has been shown that the GA undergoes morphological plastic-
ity processes that affect the GA shape and protein content under differ-
ent physiological and pathological conditions (Anton-Fernandez et al.,
2015; Fan et al., 2008; Glick, 2002; Levine et al., 1995). In different neu-
rological diseases, including Alzheimer's disease (AD), the GA of certain
populations of neurons becomes fragmented (Baloyannis, 2014; Dal
Canto, 1996; Fan et al., 2008; Fujita et al., 2006; Fujita and Okamoto,
2005; Fujita et al., 2002; Gonatas et al., 1998b; Gonatas et al., 2006;
Gonatas et al., 1992; Hu et al., 2007; Huse et al., 2002; Liazoghli et al.,
2005; Mizuno et al., 2001; Rabouille and Haase, 2015; Sakurai et al.,ircuitos corticales, Centro de
, Pozuelo de Alarcón, Madrid,
ect.com).
. This is an open access article under2000; Stieber et al., 1996). Several studies carried out in animal models
of AD have related this fragmentation to the accumulation of either am-
yloid β (Aβ) or hyperphosphorylated microtubule-associated protein
tau—the two main pathological hallmarks of AD (see Jiang et al., 2014;
Joshi andWang, 2015; Liazoghli et al., 2005). However, the precise tem-
poral sequence and the possible relationships between GA fragmenta-
tion and the accumulation of Aβ plaques or neuroﬁbrillary tangles of
hyperphosphorylated tau during the evolution of AD have not been
fully characterized.
Proper functioning of the GA is necessary for Aβ production and for
trafﬁcking andmaturation of amyloid precursor protein APP and its pro-
cessing enzymes (Burgos et al., 2010; Choy et al., 2012; Greenﬁeld et al.,
1999; Huse et al., 2002; Joshi et al., 2015). In addition, studies using the
APPswe/PS1ΔE9 animal model of the disease have reported that the ac-
cumulation of Aβ peptides leads to Golgi fragmentation, mediated by
cdk5-dependent phosphorylation of Grasp 65, which in turn accelerates
APP trafﬁcking and Aβ production (Joshi et al., 2015; Joshi and Wang,
2015). Furthermore, the integrity of the microtubule (Burkhardt,
1998; Cole et al., 1996) and actin (Egea et al., 2006) cytoskeleton is nec-
essary for the maintenance of the structural characteristics and the po-
sitioning of the GA. Various studies have suggested the existence ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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organization and GA fragmentation. For instance, it has been proposed
that the microtubule-interacting protein tau, which is localized on GA
membranes along with many of the tau phosphorylation-related ki-
nases participates in the association between Golgi membranes andmi-
crotubules (Farah et al., 2006). It has been suggested that tau pathology
precedes GA fragmentation since, in animal models of AD, the overex-
pression of tau induced GA fragmentation (Liazoghli et al., 2005; Lin et
al., 2003). However, other studies showing tau hyperphosphorylation
after brefeldin A or nocodazole treatments of HEK293/tau cells led to
the suggestion that tau hyperphosphorylation is a downstream event
that is a consequence of the disorganization of the GA (Sutterlin et al.,
2002; Jiang et al., 2014).
Pioneering studies in AD patients reported that the alterations (in-
cluding fragmentation and decreases in size) of the GA of hippocampal
neurons are unrelated to the content of intracellular NFT in CA1 hippo-
campal ﬁeld (Salehi et al., 1995) or preferentially associated with neu-
rons devoid of NTF in the subiculum and entorhinal cortex (Stieber et
al., 1996). However, during the course of our research into the possible
alterations of the GA in the hippocampus and neocortex of AD patients
using different methodological approaches to those used by Salehi et al.
(1995) and Stieber et al. (1996), we found that the progressive accumu-
lation of phospho-tau may be associated with the fragmentation of the
GA. Thus, in the present study, we have reexamined this issue using
double immunoﬂuorescence techniques, high-resolution confocal mi-
croscopy and 3D reconstruction and quantiﬁcationmethods tomeasure
the volume and surface area of theGA in neurons from control cases and
from AD patients with pre-tangle and tangle stages of
hyperphosphorylated tau accumulation. To label the GA, we used anti-
bodies that recognizeMG160, an integralmembraneGolgi protein com-
monly used as a GAmarker (Anton-Fernandez et al., 2015; Burrus et al.,
1992; Gonatas et al., 1998a; Gonatas et al., 1995; Stieber et al., 1995;
Stieber et al., 1996; Yamaguchi et al., 2003; Zhou et al., 1997; Zuber et
al., 1997).
Importantly, differences in age (Jiang et al., 2014),ﬁxation procedure
and postmortem period prior to ﬁxation might affect the structural
characteristics of the GA. These factors vary between the control and
the AD patient groups used in previous reports (Ellisman et al., 1987;
Salehi et al., 1995; Stieber et al., 1996) and might also affect the mor-
phology of the GA, as evaluated in the present study by the expression
of MG160. Therefore, in order to evaluate the possible inﬂuence of nor-
mal aging and the postmortem delay period on the analysis of MG160
expression in the GA and discriminate the interference between these
potential changes and those associated with the course of AD, we have
analyzed the GA in brain sections from C57BL/6J mice with different
ages and from mice with different postmortem times before brain
ﬁxation.
The results of the present study indicate that, in AD patients, the GA
of numerous cortical and hippocampal neurons undergo speciﬁc and
profound alterations including fragmentation and a decrease in the vol-
ume and surface area of the elements that are immunoreactive for
MG160. These changes are likely to affect the protein processing, glyco-
sylation and sorting (Wang et al., 2008; Xiang et al., 2013) and aremore
pronounced and more frequently found in neurons with a progressive
accumulation of hyperphosphorylated tau. Therefore, the perturbation
of the microtubule network by tau hyperphosphorylation could alter
GA structure and the secretory pathway, impairing the highly regulated
processes of protein sorting in neuronal compartments.
2. Materials and methods
Human brain tissuewas obtained at autopsy from two sources: from
seven patientswith AD (aged 64–89) and from control human brain tis-
sue from ﬁve individuals (aged 40–66) who died due to an accident or
other cause and were free of any known neurological or psychiatric ill-
ness (Table 1). The AD brain and some control brain tissues wereobtained from the Instituto de Neuropatología (Dr. I. Ferrer, Servicio de
Anatomía Patológica, IDIBELL-Hospital Universitario de Bellvitge, Barcelo-
na, Spain; IF4, IF10, IF12, IF13 andM16 cases), from the Banco de Tejidos
FundaciónCIEN (Dr. A. Rábano, Área de Neuropatología, Centro Alzheimer,
Fundación Reina Soﬁa,Madrid, Spain; Vk11 case) and from theNeurolog-
ical Tissue Bank (Biobanc-Hospital Clínic-IDIBAPS, Universidad de Barce-
lona, Spain; Bcn 5, Bcn7, Bcn8, Bcn13 cases). Control human brainswere
also obtained from Dr. Ricardo Insausti, Facultad de Medicina,
Universidad UCLM (Albacete, Spain; AB1, AB2). Following neuropatho-
logical examination, the AD stages were deﬁned according to the
CERAD (Consortium to Establish a Registry for Alzheimer's Disease;
(Mirra et al., 1991) and the Braak and Braak criteria (Braak and Braak,
1995); Table 1). Information regarding TDP43 inclusions was available
for four of the seven patients used (Bcn5, Bcn7, Bcn8 and Bcn13).
None of them showed TDP43 inclusions in CA1 or temporal neocortex,
and only Bcn7 had TDP43 inclusions in neurons of the amigdala.
The postmortem delay between death and tissue processing ranged
between 1.5 and 5.5 h (Table 1), and the brain samples were obtained
following the guidelines of the Institutional Ethical Committees, which
also granted approval. Tissue from some of these human brains has
been used in previous studies (Blazquez-Llorca et al., 2010;
Blazquez-Llorca et al., 2011).
Upon removal, the brainswere immediatelyﬁxed in cold 4% parafor-
maldehyde in phosphate buffer (PB: 0.1M, pH7.4), and after 2 h, the tis-
suewas cut into small blocks and post-ﬁxed in the same ﬁxative for 24–
48 h at 4 °C. However, one human patient (AB1)was intraarterially per-
fused through the internal carotid arthery b1 h after death with a saline
solution followed by 4% paraformaldehyde in PB. The brainwas then re-
moved and post-ﬁxed as mentioned above. After ﬁxation, all the speci-
mens were immersed in graded sucrose solutions and stored in a
cryoprotectant solution at−20 °C. Serial sections (50 μm)of the cortical
tissue were obtained using a vibratome (St. Louis, MO, USA), and the
sections from each region and case were batch-processed for immuno-
histochemical staining. The sections immediately adjacent to those
stained immunohistochemically were Nissl-stained in order to identify
the cortical areas and the laminar boundaries.
2.1. Immunoﬂuorescence
For immunoﬂuorescence experiments, free ﬂoating serial sections
(50-μm thick) were ﬁrst rinsed in PB and then pre-treated in 1.66%
H2O2 for 30 min to inactivate the endogenous peroxidase activity and
were then preincubated for 1 h in PB with 0.25% Triton-X100 and 3%
normal serum of the species in which the secondary antibodies were
raised (Vector Laboratories, Burlingame, CA, USA). The sections were
then incubated for 48 h at 4 °C in the same stock solution containing
the following primary antibodies in the combinations indicated: rabbit
anti-MG160 (Abcam, 1:100), mouse anti-NeuN (Chemicon, 1:2000),
mouse phospho-PHF-tau pSer202 + Thr205 antibody (AT8, 1:2000,
Pierce Endogen).
After rinsing in PB, the sections were incubated for 2 h at room tem-
perature in the appropriate combinations of Alexa 488- or Alexa 594-
conjugated goat anti-mouse or goat anti-rabbit antibodies (1:2000;Mo-
lecular Probes, Eugene, OR, USA). Sections were also stained with a nu-
clear stain DAPI (4,6-diamidino-2-phenylindole; Sigma, St. Louis, MO,
U.S.A.). After rinsing in PB, the sections were treated with Autoﬂuores-
cence Eliminator Reagent (Chemicon) to reduce autoﬂuorescence,
mounted in antifade mounting medium (ProlongGold, Invitrogen) and
studied by confocal microscopy (Zeiss, 710).
From the temporal neocortex and the CA1 region of the hippocam-
pus, we obtained image stacks recorded at 0.35 μm intervals through
separate channels with a 63x oil-immersion lens (NA, 1.40, refraction
index, 1.45). The number of optical planes in the confocal stacks ranged
from 40 to 142 (mean= 84.5) in the neocortex and 69 to 183 (mean=
108.3) in the hippocampus. ZEN 2012 software (Zeiss) was used to con-
struct composite images from each optical series by combining the
Table 1
Summary of clinical and surgical data. Neurological diagnosis deﬁned according to Braak and Braak criteria (Braak and Braak, 1995), deﬁned by different stages (from I to VI) and also
according to CERAD criteria (Consortium to Establish a Registry for Alzheimer's Disease; Mirra et al., 1991), which use a semi-quantitative score of the density of neuritic plaques in
the most severely affected region of the isocortex (A =mild presence of plaques, B = moderate presence of plaques, C = severe presence of plaques).
AD patients Cortical area Age (years) Gender Postmortem delay Neurological diagnosis Cause of death
Bcn5 Area 21 83 Female 4 h AD V/VI – C Respiratory infection
Bcn7 Area 21 89 Female 4/4.5 h AD VI – C –
Bcn8 Area 21 85 Female 5/6 h AD VI – C –
P3 (IF4) Area 22 80 Female 3 h AD III – B Pneumonia
P11 (IF13) Area 20/21 75 Male 2 h AD III – B Lymphoproliferative disorder
P13 (Bcn13) – 83 Male 2.5 h AD –
P14 (Vk11) Area 20/21 87 Female 1.5 h AD III/IV – A Respiratory infection
Non-demented cases
AB1 Area 21 45 Male b1 h – Pleural mesothelioma
AB2 Area 21, 38 50 Female 4 h – Septic shock of pulmonary origin
M16 Area 20 40 Male – – Trafﬁc accident
C7 (IF10) Area 20 66 Male 2 h – Bilateral pneumonia plus cardiac post-transplant
P10 (IF12) Area 20/21 52 Male 2 h – Carcinoma – bronchopneumonia
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ware was used to obtain Z projection images (image resolution:
1024 × 1024 pixels; pixel size: 0.11 μm). Adobe Photoshop (CS4)
software was used to compose ﬁgures.
2.2. Image analysis and statistics
Fiji software (3D object counter tool) was used to analyze the vol-
ume and surface area of the elements immunostained for the different
GA markers in image stacks according to a previous study (Anton-
Fernandez et al., 2015). A limitation of the present study is that unfortu-
nately the combinations of antibodies used, known towork satisfactori-
ly in human brain tissue, did not allow the simultaneous visualization of
the GA (MG160), the neuronal somata (NeuN) and phospho-PHF-tau
(AT8). Despite this, we cropped 3D substacks from the original confocal
stacks taken from AT8-MG160 double-stained sections counterstained
with DAPI, trying to limit the analysis to the complete GA corresponding
to the somata of single neurons. These cells included neurons
without hyperphosphorylated tau (AT8−) and neurons with
hyperphosphorylated tau (AT8+) at different stages (non-tangle-
bearing neurons and tangle-bearing neurons; see Table 2 for the
number of neurons of each type analyzed for all of the brain regions
and cases studied). To make sure that we analyzed complete cell
bodies, the substacks were centered on the location of those single
DAPI-stained neuronal nuclei that were separated in all dimensions
from the edges of the stack by at least 10 μm. From these positions,
we analyzed the whole thickness of the confocal stacks and we de-
ﬁned the limits of every image substack according to the ‘reach’ of
the MG160-ir elements surrounding the selected neuronal nuclei.
The number of optical planes in the cropped confocal substacks
ranged from 10 to 62 (mean = 52) in the neocortex and 15 to 89
(mean = 40) in the hippocampus. We selected isolated neurons
that were separated from other neurons by neuropil, in order to
avoid the inclusion of MG160-ir elements belonging to neighboring
neurons. For this purpose, in AT8+ neurons, the presence of AT8 im-
munostaining helped to identify the limits of the neuronal somata. InTable 2
Table showing the percentages and total number (in parenthesis) of pyramidal neurons analyz
showing the relationship between the appearance of Golgi apparatus (GA) (NF, non-fragmented
tauAT8 (AT8−, type I and II).
Ctx
NF F
Control 91.6 (296) 7.4 (24)
Patients All cell types 58.7 (430) 24 (176)
AT8− 71.8 (412) 21.9 (126)
AT8+ Type I 25.4 (14) 40 (22)
Type II 3.9 (4) 26.9 (28)AT8− neurons, background MG160 staining also helped to distin-
guish neuronal somata from neuropil. To determine differences be-
tween values obtained in AT8− neurons and AT8+ non-tangle-
bearing and tangle-bearing neurons, paired Friedman analysis of
variance tests were performed using SPSS software (version 22).
When the Friedman test was signiﬁcant, a Wilcoxon matched pair
test was performed between groups.
2.3. Aging and postmortem autolysis effects on Golgi apparatus
The human tissue used in the present study came from patients who
died at different ages and with different postmortem delay periods until
brain ﬁxation—up to 6 h in some cases (Table 1). Thus, in order to test the
possible involvement of aging and postmortem autolysis effects on the
structure of the neuronal GA, and to discriminate between these effects
and those related toAD, in thepresent studyweanalyzedGA immunostain-
ing in two groups of mice. These experiments were performed in accor-
dance with the guidelines established by the European Union regarding
the use and care of laboratory animals (86/609/EEC) and the experimental
procedureswere approvedbyour institutional animal useandcare commit-
tee. Special care was taken to minimize animal suffering and to reduce the
number of animals used to the minimum required for statistical accuracy.
In order to test possible effects of aging on the GA of pyramidal neu-
rons, we analyzed C57BL/6J mice (Charles River Laboratories, Wilming-
ton,MA) at different ages: 8, 32, 60 and 80weeks (three animals per age
group). Animals were sacriﬁced by a lethal intraperitoneal injection of
sodium pentobarbital (200 mg/kg b.w.) and were then perfused intra-
cardially with a saline solution followed by 4% paraformaldehyde in
PB. The brain of each animal was removed, post-ﬁxed by immersion in
the sameﬁxative for 24 h at 4 °C, cryoprotected in 30% sucrose and serial
coronal sections (50-μm thick) were obtained with a freezing sliding
microtome (Microm HM 450, Microm International, Germany).
To assess post-mortem time-induced effects on the structure of the
GA, two-month-old male C57BL/6J mice (n = 3, per group) (Charles
River Laboratories) were used. Mice were deeply anaesthetized with a
pentobarbital lethal injection (200 mg/kg b.w, Vetoquinol, Madrid,ed, from the CA1 and temporal neocortex of control cases and Alzheimer disease patients,
; F, fragmented; HA, highly altered) with the different patterns of immunostaining for PHF-
CA1
HA NF F HA
1 (3) 75.78 (144) 22.6 (43) 1.6 (3)
17.3 (127) 33.09 (236) 43.19 (308) 23.7 (169)
6.3 (36) 47.9 (201) 45.7 (192) 6.4 (27)
34.5 (19) 16.6 (28) 46.7 (79) 36.7 (62)
69.2 (72) 5.7 (7) 29.8 (37) 64.5 (80)
Fig. 1.DistributionofMG160 in theGAofhumanpyramidalneuronsA–F:Triosof confocal stackprojection images taken fromthe temporalneocortex(A–C)and theCA1hippocampal region (D–F)of
sectionsdouble-immunostained forMG160/NeuNandcounterstainedwithDAPI showing thedistributionofMG160 in theGA. Scalebar inF indicates18 μminA–Cand16μminD–F.G–J:Histograms
showing surface area (G, I) and volume (H, J) values (mean ± SE) of GA elements immunoreactive for MG160, obtained from cropped confocal image stacks including complete single pyramidal
neurons from temporal neocortex (black bars; total n = 323) and CA1 (white bars; total n = 189). G and H show the statistical comparisons of mean values (surface area and volume,
respectively) between neocortical and hippocampal neurons. I and J show the comparisons of the values obtained across the different cases in each region (Friedman test, *p ≤ 0.01; **p ≤ 0.001).
Note that in all cases the surface area and volume values of MG160-ir elements in CA1 are higher than in neocortical pyramidal cells (G, H) despite the inter-individual differences (I, J).
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Fig. 2.Morphological types of Golgi apparatus Confocal stack projectionmages taken from the temporal neocortex of sections from control cases, double-immunostained forMG160/AT8
showing examples of neurons with a non-fragmented (A), fragmented (B) or highly altered (C) GA. Scale bar indicates 4,8 μm.
15A. Antón-Fernández et al. / Neurobiology of Disease 97 (2017) 11–23Spain). The cadavers were subjected to different post-mortem times
and temperature conditions. Two groups of mice were maintained
at room temperature for 0.5 and 2 h, respectively. A third group
was kept at room temperature for 2 h followed by 3 h at 4 °C in a
fridge. The brains were then removed from the skull and ﬁxed by
immersion with 4% paraformaldehyde for 20 h at 4 °C. After ﬁxa-
tion, brains were cryoprotected in 30% sucrose and then ﬂash-fro-
zen in isopentane (2-methylbutane, Merck, Billerica, MA), cooled
in a 70% ethanol dry ice bath, and stored at−80° until cutting. Cor-
onal sections (30 μm) were cut with a freezing sliding microtomeFig. 3.Distribution ofMG160 in theGAof AT8− andAT8+humanneocortical pyramidal neuron
neocortex of sections double-immunostained forMG160/AT8 showing thedistribution ofMG16
indicates 6.4 μm in A and B, 9.1 μm in C and D, 8.1 μm in E and F, 9.6 μm in G and H and 8.8 μm(Microm HM450). Sections from all animal groups were immuno-
cytochemically stained as described above using anti-MG160 anti-
bodies. Confocal image stacks were taken from the temporal
neocortex and the hippocampal formation and were analyzed in
the same way as described for the human tissue (see above). To de-
termine differences between values obtained in animals with dif-
ferent postmortem delay times as well as in mice groups with
different ages, Kruskal-Wallis one-way analysis of variance was
performed followed by Bonferroni-corrected Mann-Whitney U
test, using SPSS software.s A, B; C, D; E, F;G,H; I, J: pairs of confocal stack projection images taken from the temporal
0 in theGA ofAT8−, and AT8+(type I and type II) pyramidal neurons. Scale bar shown in J
in I and J.
Fig. 4.Measurements of theGA in neocortical pyramidal neurons fromADpatients A andB: histograms show comparisons in surface area (A) and volume (B) values ofMG160-ir elements
between neurons with non-fragmented, fragmented or highly altered GA in AD cases (Friedman test, *p ≤ 0.01; **p ≤ 0.001). C–D: histograms showing, on the left side, surface area (C) and
volume (D) values (mean±SE) ofMG160-ir GA elements, in control (white bars, n=323) and AD(patterned bars, n=733) pyramidal neurons from temporal neocortex. Note that Golgi
elements had a higher surface area (but not volume) in control than in neurons from ADpatients. Also note (in the histograms on the right) that for ADneurons (taking all cases together)
both surface area and volume valueswere reduced in AT8+ (especially in type II) neurons, compared to AT8− neurons. Note that in E and F there was a tendency for this reduction in all
AD patients analyzed, with statistically signiﬁcant differences between the different cell types of each patient in ﬁve out of the six cases analyzed (Friedman test, *p ≤ 0.01; **p ≤ 0.001).
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3.1. Distribution of MG160 in the GA of control human cortical neurons
To characterize alterations in the Golgi apparatus (GA) of AD pa-
tients, we ﬁrst studied its normal morphological characteristics in neo-
cortical and hippocampal pyramidal neurons from human control
autopsy cases. We studied sections stained with DAPI and double-im-
munostained with antibodies that recognize the neuronal marker
NeuN and MG160, a sialoglycoprotein that is frequently used as a GA
marker and is mainly localized in the medial cisternae of the GA (Fig.
1). The identiﬁcation of pyramidal neurons relied on the presence of
an apical dendrite. MG160-ir GA elements were located in the neuronal
cytoplasm, as deﬁned by the NeuN immunostaining, usually in aperinuclear position. We found a signiﬁcant variability in the morpho-
logical characteristics of GA elements that were immunoreactive (ir)
for MG160, which we qualitatively subdivided into three different mor-
phological types (Fig. 2, Table 2):
1) neurons with a GA that showed a normal non-fragmented (NF in
Table 2, arrows in Fig. 2A) appearance, consisting of a network of twist-
ed and convoluted cisternae and tubular structures with a ribbon-like
appearance that was distributed throughout the cell body and partially
extended to the apical dendrite.
2) neurons with a fragmented (F in Table 2, arrowheads in Fig. 2B)
GA—without ribbon-like appearance andoften showing a variable num-
ber of independent elements with globular appearance dispersed
throughout the soma—that were more abundant in CA1 than in the
neocortex.
17A. Antón-Fernández et al. / Neurobiology of Disease 97 (2017) 11–233) neurons in which the GA, as identiﬁed by MG160 immunostain-
ing, was very scarce or had a highly altered (HA) morphology (HA in
Table 2, asterisks in Fig. 2C).
The percentage of neurons with a non-fragmented GA was higher in
the temporal neocortex than in the CA1 hippocampal ﬁeld (Table 2). In
addition, GA of neocortical neurons (Fig. 1A–C) showed a less complex
appearance, that is, with a lower degree of cisternae extension and con-
volution than in the case of hippocampal neurons (Fig. 1D–F).
To further characterize the GA in control neocortical and hippocam-
pal CA1 pyramidal neurons, we used the 3D object counter tool in the
Fiji software package to quantify the volume and surface area of
MG160-ir GA elements of the different control human brains (Figs.
1G–J). We found a signiﬁcantly larger volume and surface area of
MG160-ir elements in CA1 hippocampal neurons than in neurons
from temporal neocortex (Fig. 1G, H). We found the same trend when
data from different control cases were analyzed separately (Fig. 1G,
H). We also compared the mean values for the surface and volume of
theMG160-ir GA elements between the different cases. Both in neocor-
tical and CA1 pyramidal cells, these values were very homogeneous
across cases with only few inter-individual comparisons yielding statis-
tically signiﬁcant differences (Fig. 1I, J).
3.2. Alterations inMG-160 distribution in the GA of neurons fromAlzheimer
disease patients
According to previous studies (Salehi et al., 1995; Stieber et al.,
1996), the GA in neurons from AD patients is altered, usually showing
a fragmented appearance in some cortical neurons. In the present
study we found that the fragmentation of the GA in some neurons,
both in neocortex and CA1 pyramidal neurons, was apparently associat-
ed with a reduction in the size of the GA (Fig. 4A, B). The surface area
and volume of the GAwas reduced in fragmented neurons (only in tem-
poral neocortex), and especially in highly altered neurons, as compared
with non-fragmented neurons (Fig. 4A, B).
The possible relationship between GA fragmentation and the pro-
gressive neuronal accumulation of hyperphosphorylated tau protein
has not been explored thoroughly in previous studies. Here,we have an-
alyzed this relationship both in pyramidal neurons from temporal neo-
cortex and CA1 of AD patients, in confocal stacks taken from sections
with double immunoﬂuorescence staining using antibodies directed to
MG160, and AT8 antibodies which recognize phospho Ser202 and
phospho Thr205 sites in microtubule-associated tau protein (Figs. 3–
5), and counterstainedwithDapi. According to oneof our previous stud-
ies (Blazquez-Llorca et al., 2010), it is possible to distinguish between
AT8-negative neurons and two types of tau AT8-ir neurons showing dif-
ferent patterns of immunostaining for paired helical ﬁlaments (PHF):
pattern I, which have diffuse cytoplasmic staining with no ﬁbrillar ag-
gregates (pre-tangle stage) and pattern II, which typically formNTF. Re-
garding GA fragmentation—considering all cell types analyzed in AD
patients—we found that, as in control cases, the percentage of neurons
with a fragmented and highly altered GAwas higher in CA1 than in tem-
poral neocortex (Table 2). Considering neurons with different patterns
of PHF-tauAT8 immunostaining separately, we found that the percent-
age of neuronswith a normal, non-fragmentedGAappearancedecreased
in AD patients, even in AT8-negative neurons, as compared to controls,
indicating a generalized alteration of GA in AD (Table 2). In addition, we
observed that, compared to AT8-negative neurons, the percentage of
neocortical and hippocampal neurons showing a highly altered GA was
higher in those neurons with hyperphosphorylated tau (both in type I
and more markedly in type II neurons) (Table 2, Figs. 3, 5).
We also found a general drop in surface area and volume ofMG160-
ir GA elements in neocortical and hippocampal neurons from AD pa-
tients compared to neurons from control cases (Figs. 4C–D, 5G–H). In
order to determine if there was a speciﬁc deleterious effect of the accu-
mulation of hyperphosphorylated tau on the GA in AD patients, we an-
alyzed these data distinguishing between cells in pre-tangle stage (typeI, Figs. 3, 5D) and in tangle stage (type II, Figs 3, 5). According to the
above qualitative analysis, the results showed a progressive decline in
the mean surface area and mean volume of MG160-ir GA elements
from AT8− to type I and, more markedly, type II AT8-positive
neurons—both in the temporal neocortex (Fig. 4C,D) and in CA1 (Fig.
5G,H). To evaluate the possible inﬂuences of inter-individual variability
on these results, we analyzed separately data obtained from the differ-
ent AD patients. The results showed a similar trend in all patients,
with the decrease in surface area and volume of GA reaching statistical
signiﬁcance in most (but not all) of the patients (Figs. 4E–F, 5I–J).
3.3. Alterations of the Golgi apparatus in neurons with
hyperphosphorylated tau in a non-demented case
To test in human tissue the effects induced by the sole presence of
the aggregation of hyperphosphorylated tau (presumably without any
other possible pathologic factors present in the AD such as the presence
of β-amyloid plaques), we studied themorphological features of neuro-
nal GA in a human brain from a 45-year-old male adult whowas free of
anyneurological or psychiatric disease (not diagnosedwith AD) and had
died froma lung tumor (AB1, see Table 1). In the brain of this patient, we
found a relatively large number of neurons with intracellular aggrega-
tion of hyperphosphorylated tau protein in temporal (Brodmann areas
20, 21, 22 and 38), prefrontal (9, 10 12) and frontal (areas 44, 45, 46
and 47) cortical areas while they were not detected in other cortical re-
gions such as the primary motor (area 4), primary somatosensory (area
3b), primary visual (area 17) cortical areas. No β-amyloid plaques were
found in any of these regions. In confocal stacks taken from sections dou-
ble-immunostained forMG160 andhyperphosphorylated tau (AT8 anti-
bodies), we obtained surface area and volume values of MG160-ir GA
elements (Fig. 6J–K) in neurons with phospho-tau (in pre-tangle (I)
and tangle (II) stages) and without phospho-tau, in CA1 (Fig. 6A–C).
Values were also obtained in the temporal neocortex, in area 22 (Fig.
6D–F) and in area 38 (Fig. 6G–I), where tau-ir neurons were more
abundant. The results in the three regions analyzed showed a general
reduction in surface area and volume measurements of MG160-ir in
AT8+ neurons, which reached statistical signiﬁcance only in the
type II pattern of AT8 immunostaining, that is, in neuroﬁbrillary tangle-
bearing neurons (Fig. 5J–K).
Consequently, these results further support the idea that the aggre-
gation of hyperphosphorylated tau may exert a speciﬁc deleterious ef-
fect on the morphological features of the GA in cortical neurons,
which might contribute to neuronal dysfunction and degeneration in
AD.
3.4. Effects of aging and postmortem delay on the morphological features of
the neuronal GA
The differences in the size and fragmentation of the GA found be-
tween control and AD cases, and even the inter-individual differ-
ences found within each group, could be partially due to the
differences in age of the patients and/or postmortem delay before
ﬁxation procedures. Fixation by immersion might also contribute
to the differences in the GA between neocortical and CA1 hippo-
campal neurons (Table 2) as a consequence of the deeper localiza-
tion of CA1 compared to the neocortex. Therefore, to evaluate the
potential contribution of these factors to the observed differences
and to help elucidate those alterations that were due to the course
of the disease, we next used C57BL/6J mice with different ages (2,
8, 15 and 20 months, Fig. 7A, B, E, F) and young adult mice brains,
which were extracted and ﬁxed by immersion after different post-
mortem delays (Fig. 7C, D, G, H). We measured the surface area
and volume of the MG160-ir GA elements in CA1 and CA3 hippo-
campal neurons and supra- and infra-granular pyramidal neurons
from somatosensory cortex in confocal stacks taken from sections
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(AT8 antibody).
As expected, in all regions and ages analyzed we found no AT8
immunostaining above background levels. That is, all neurons ana-
lyzed were AT8 negative. In addition, the GA of neurons in all regions
and age groups had a normal, non-fragmented appearance (Fig. 7A,
B). The quantitative analysis revealed no differences between the
different age groups in terms of the surface area and volume of
MG160-ir elements of supragranular pyramidal neurons (Fig. 7E,
F). However, a tendency for a reduction with age in the size of the
GA, as judged by MG160 immunostaining, was found in pyramidal
neurons from infragranular neocortical layers and the CA3 region.
This reduction was more marked in pyramidal neurons from CA1
(Fig. 7E, F). Finally, we found that the surface area and volume of
MG160-ir GA elements of pyramidal neurons were sensitive to the
post-mortem delay period, as they were signiﬁcantly reduced, in all
regions examined, in animals with postmortem periods of 2 h and
5 h as compared with those with a delay of 30 min before ﬁxation
(Fig. 7G, H).
4. Discussion
The present results show that MG160 is widely expressed in the GA
of human and mouse neocortical and hippocampal neurons. Using this
protein as a GA marker, we showed by immunoﬂuorescence, confocal
microscopy and 3D quantiﬁcation that, in both species, both the volume
and surface area of the GA in CA1 hippocampal neurons are larger than
in neocortical neurons, which is in line with previous studies in the ce-
rebral cortex of Syrian hamsters (Anton-Fernandez et al., 2015). The
present study also shows that the GA in mouse neocortical neurons is
sensitive to aging and delay time prior to ﬁxation—a sensitivity which
is even more marked in the case of hippocampal neurons. These factors
should therefore be taken in consideration when analyzing the differ-
ences in the size of the GA between human control neurons and those
from AD patients (see below) or when comparing animal models of
AD with patients, as the brain from animal models is commonly ﬁxed
by perfusion with no postmortem period.
In human control cases we also found that the GA of b10% of the
neocortical neurons analyzed displayed a fragmented or highly altered
appearance with a concomitant reduction in volume and surface area
of the MG160-ir elements with respect to neurons with a non-
fragmented GA. We consider that these alterations of the GA could be a
consequence of the postmortem delay time before ﬁxation. In the case
of CA1 hippocampal neurons, the percentage of neuronswith an altered
GA was almost 25%—markedly higher than in the neocortical neurons.
This observation could be related to the deeper position of CA1 com-
pared to the more superﬁcial location of the neocortex and the conse-
quent longer period prior to ﬁxation of the hippocampus by
immersion or it may be that the hippocampal neurons are more sensi-
tive to postmortem factors than the neocortex.
Our results also show that, in both temporal neocortex and hippo-
campus, the percentage of neurons with a fragmented GA was higher
in brain samples from AD patients than in human control tissue. This
is in general agreement with previous studies showing GA fragmenta-
tion in neurons from AD patients, which suggested an important role
of GA fragmentation in the neuropathology and pathogenesis of AD
(Baloyannis, 2014; Salehi et al., 1995; Stieber et al., 1996). GA fragmen-
tation in our material was associated with important reductions in theFig. 5. Distribution of MG160 in the GA of AT8− and AT8+ human CA1 pyramidal neurons
hippocampal CA1 region double-immunostained for MG160/AT8 showing the distribution of M
F indicates 20 μm in A–D and C–F, and 19 μm in B–E. Histograms showing, on the left side, hi
control (white bars, n = 189) compared with AD (patterned bars, n = 713) CA1 pyramidal ne
area and volume values were reduced in AT8+ (especially in type II) neurons, compared t
patients analyzed, with statistically signiﬁcant differences between the different cell types of evolume and surface area of the MG160-expressing elements of the GA.
Considering that (1) there was a signiﬁcant difference in age between
the control group and the AD patients used both in previous reports
(Stieber et al., 1995) and in the present study (control, mean ± SD:
50.6 ± 9.8 years; AD, mean ± SD 83.1 ± 4.6 years) and (2) a decrease
in volume and surface area of MG160-ir GA elements was observed in
agedmice in CA1 in the presentwork, we cannot rule out the possibility
that the decreases observed in AD patients—especially those in the CA1
region—could be in part due to aging of AD patients and not a conse-
quence of the disease itself. However, this is unlikely since fragmenta-
tion of the neuronal GA from AD patients was also reported in a study
using groups of control subjects and AD patients with no differences
in age (Salehi et al., 1995). Postmortem time prior to ﬁxation also af-
fect themorphological features of the GA (present results). However,
in the present study, there were no differences in this parameter be-
tween the control and AD cases and they is therefore not considered
to be a factor contributing to the observed differences in GA volume
and surface area.
4.1. GA fragmentation and immunostaining for AT8
Thepresentwork also showed that GA fragmentation and signiﬁcant
reductions in the volume and surface area of the MG160-expressing el-
ements of the GAweremore pronounced in neuronswith a progressive
accumulation of phospho-tau (that is, pretangle and tangle states, as re-
vealed by AT8 antibodies that detect phosphorylations in Ser202/
Thr205) than in AT8-negative neurons. This observation supports the
idea that the aggregation of hyperphosphorylated tau may exert a spe-
ciﬁc deleterious effect on themorphological features of theGA. This is in
partial disagreement with pioneering studies in AD patients reporting
that the alterations (including fragmentation and decreases in size) of
the GA of hippocampal neurons are unrelated to the content of intracel-
lular NFT in the CA1 hippocampal ﬁeld (Salehi et al., 1995) and prefer-
entially associated with neurons devoid of NTF in the subiculum and
entorhinal cortex (Stieber et al., 1996). Methodological differences
might contribute to the discrepancies between the present work and
these two studies as they were carried out in parafﬁn-embedded brain
tissue blocks fromADpatientswith heterogeneous postmortemperiods
and ﬁxed in formaldehyde for over 1 month. Furthermore, the size of
the GA was estimated in 2D in 5-6 μm-thick sections, and therefore
the cell body of the pyramidal cells examined was likely incomplete as
the diameter of the soma of the majority of pyramidal cells is larger
than 5 μm,whereaswemade full 3D reconstructions using confocal mi-
croscopy. In addition, the identiﬁcation of the GA with conventional
light microscopy relied on its immunocytochemical staining using
light opaque chromogens as well as the subsequent (Salehi et al.,
1995) or simultaneous (Stieber et al., 1996) staining of intracellular
NFTs using, respectively, the silver Bodian technique or histochemical
methods with a different colored chromogen. The ﬁxation procedures
used in these studies might have affected the preservation of the GA
and the sectioning and staining methods used may have interfered
with the measurement of the size of the GA or the assessment of the
level of tau hyperphosphorylation.
In the present study, the 3D segmentation of the GA elements was
based on the observed threshold selection of ﬂuorescent labeling. The
threshold selection was adjusted slightly for each case, although the
quality of immunostaining was similar in all cases. In addition, the
threshold that was set for each confocal stack of images equally affectedA, D; B, E; C, F; Pairs of confocal stack projection images taken from sections from the
G160 in the GA of AT8−, and AT8+ (type I and type II) pyramidal neurons. Scale bar in
gher surface area (G) and volume (H) values (mean ± SE) of MG160-ir GA elements, in
urons. Note on the right side that for AD neurons (taking all cases together) both surface
o AT8− neurons. Note that in I and J there was a tendency for this reduction in all AD
ach patient in four out of the seven cases analyzed.
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labeling intensities inﬂuence the perceived size, the present methodol-
ogy might induce some bias in the measurement of absolute values of
GA surface area and volume. However, the main observation of the
present study—showing a progressive reduction of the GA size associat-
ed with the increase in the accumulation of phospho-tau (from
pretangle to neuroﬁbrillary tangle-bearing neurons)—was consistently
observed in all cases (see Fig. 5).
This suggests that the presence of phospho-tau aggregates might
exert a progressive damage on the GA of human neurons. This is sup-
ported by the fact that GA alterations in AD patients were more pro-
nounced in pyramidal neurons from CA1 than from the temporal
neocortex (present work) and according to Braak and Braak studies
(Braak and Braak, 1995) during the stereotypical spatiotemporal pro-
gression of AD, NFTs appear at earlier stages and progresses earlier in
CA1 than in neocortex. In addition, the speciﬁc structural alterations in
the GA observed in AT8+ NFT-bearing neocortical and hippocampal
neurons from the brain of a non-demented patient who had not been
diagnosed with AD and in the absence of β-amyloid plaques (present
work) also support the idea that the presence of NFT is by itself enough
to induce alterations on the structure of the GA. Interestingly, the rela-
tionship between tau hyperphosphorylation and GA alterations is in
agreement with different lines of evidence and has also been
established in previous studies using animal models of AD (Liazoghli
et al., 2005). For example, the transitory GA fragmentation that mi-
totic dividing cells undergo is concomitant to an increase in tau
phosphorylation, as revealed by antibodies that also recognize neu-
roﬁbrillary tangles in AD such as AT8 (Delobel et al., 2002;
Illenberger et al., 1998; Pope et al., 1994; Preuss et al., 1995; Preuss
and Mandelkow, 1998; Vincent et al., 1996). In addition, the revers-
ible alterations in volume and surface area of MG160-ir elements of
the GA during the torpor phase of hibernation has also been related
to the phospho-tau content, revealed with AT8 antibodies (Anton-
Fernandez et al., 2015).4.2. Temporal relationship between GA fragmentation and tau
hyperphosphorylation
Regarding the temporal relationship betweenGA fragmentation and
tau hyperphosphorylation, it is known that, among other factors, the in-
tegrity of the microtubule cytoskeleton determines the position and
morphological properties of the GA (Burkhardt, 1998; Cole et al.,
1996). It was suggested that tau binds Golgi membranes and microtu-
bules (Farah et al., 2006). Therefore, morphological features of the GA
might be potentially altered by the microtubule alterations induced by
tau hyperphosphorylation. It has been proposed that in AD, tau pathol-
ogy is an upstream event that precedes GA fragmentation since tau
overexpression led to the fragmentation of the neuronal GA (Liazoghli
et al., 2005; Lin et al., 2003). Nevertheless, tau hyperphosphorylation
has been reported in HEK293/tau cells—after treatments with the mi-
crotubule-depolymerizing agent, nocodazole or the Golgi-disturbing
agent, brefeldin A—which would indicate that fragmentation of GA is
an upstream event required to trigger tau hyperphosphorylation
(Jiang et al., 2014; Sutterlin et al., 2002).
Therefore, further studies should be carried out to unravel the time-
relation of tau-phosphorylation andGA alterations, due to its crucial rel-
evance for understanding pathology progression in AD.Fig. 6.Distribution ofMG160 in the GA of AT8− and AT8+ human CA1 and neocortical pyramid
from CA1 (A–C) and areas 21 (D–F) and 38 (G–I) of the temporal neocortex from sections doub
and AT8+ (type I and type II) pyramidal neurons from a human in a non-demented control ca
surface area (J) and volume (K) values (mean± SE) ofMG160-ir GA elements, in AT8− neuron
area 38, n=49; area 21, n= 12; CA1, n=47). Note that both surface area and volume values w
test, *p ≤ 0.01; **p ≤ 0.001).4.3. Alterations in the GA AT8− neurons
The present results have revealed alterations in the GA of AT8−
neurons. This is in line with the reported GA fragmentation in neurons
without NFT, identiﬁed using silver staining techniques (Baloyannis,
2014; Salehi et al., 1995) or immunostaining for bFGF (Stieber et al.,
1996). It is possible that some AT8− neurons with a fragmented or al-
tered GA might have tau that is hyperphosphorylated at residues
other than Ser202/Thr205 (which are recognized by AT8 antibodies).
Whether or not the degree of accumulation of phospho-tau that is
hyperphosphorylated at different sites is correlated with the extent of
GA alterations should be explored in further studies using PHF1 or
AT180 antibodies which recognize tau that is hyperphosphorylated at
other sites (Goedert et al., 1994).
However, other factors such as the presence of β-amyloid plaques
could be responsible for the GA fragmentation reported here in pyrami-
dal neurons that were not immunoreactive for AT8. Indeed, trafﬁcking
and maturation of APP, its processing enzymes and Aβ production
have been shown to be dependent on the integrity of the GA (Burgos
et al., 2010; Choy et al., 2012; Greenﬁeld et al., 1999; Huse et al., 2002;
Joshi et al., 2015; Joshi and Wang, 2015). In addition, in the APPswe/
PS1ΔE9 animalmodel of AD, it has been reported that the accumulation
Aβ peptide in neuronsmight induce GA fragmentation, thereby acceler-
ating the trafﬁc of APP and the production of Aβ (Joshi et al., 2015; Joshi
and Wang, 2015).
It has also been reported that approximately 50% of AD patients may
also develop TDP-43 pathology in certain brain regions (see Wilson et
al., 2011). This pathology has been found to correlate with GA fragmen-
tation in spinal cord neurons in patients with Amyotrophic lateral scle-
rosis (Fujita and Okamoto, 2005). Therefore, although TDP-43
pathology might potentially contribute to GA alterations in neurons
from AD patients, this was not the case in the four out of seven patients
used in this study for which information regarding TDP43 inclusions
was available.
Regardless of additional possible factors that might induce GA al-
terations, the present study revealed that, in neocortical and hippo-
campal neurons from AD patients, the changes in the microtubule
network related to tau hyperphosphorylation was associated with
the fragmentation and reduction in volume and surface area of the
GA.
Since the level of cell activity has been directly related to the size
of the GA (Lucassen et al., 1993; Salehi et al., 1995), the alterations of
the GA observed in the present study would likely result in a dereg-
ulation of neuronal calcium levels (Li et al., 2013) and alterations in
protein synthesis, modiﬁcation, and sorting (Salehi et al., 1995;
Wang et al., 2008; Xiang et al., 2013). This suggests that the defects
in the GA are likely to contribute to the neurotoxicity associated
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